21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer. 21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer.
The 21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer.
A common test used to decide whether breast cancer patients should get chemotherapy may be making bad recommendations for some Black women, leading them to forgo chemotherapy when it might have helped, according to new research from the University of Illinois Chicago.